Mirador Therapeutics is focused on delivering first- and best-in-class therapeutics for Crohn’s disease, ulcerative colitis, rheumatoid arthritis, idiopathic pulmonary fibrosis, and other immuno-fibrotic conditions. Its Mirador360 (M360) discovery and development engine combines more than 2.5 million patient profiles with advanced machine learning to uncover novel targets, stratify patients, and design rational drug combinations. In less than two years, the company has advanced multiple clinical-stage assets and is pursuing a parallel development strategy that aims to generate ten or more clinical readouts by the end of 2027. Management positions the approach as a step-change over incremental monotherapies, seeking to redefine precision medicine in immunology and inflammation. Mirador has raised over $650 million since launching in March 2024, enabling it to fund proof-of-concept studies across its current portfolio and add new pipeline candidates. The company operates with an emphasis on capital efficiency and disciplined execution to sustain momentum. Mirador is headquartered in San Diego, California.

Total raised

$650M

Funding rounds

2

Latest round

Series B

Latest activity

Jan 2026